45 results about "Hypoxia reoxygenation" patented technology

The invention provides a method for making high-purity camellin A and camellin B. The method is as follows: Adinandra nitida is used as a raw material and is extracted by a hydroalcoholic solvent system; then, the raw material is extracted and degreased by a semipolar organic solvent after depressurized concentration; water-phase continuous concentration of Adinandra nitida total flavone is carried out, and the total flavone is recrystallized to obtain camellin A through a hydroalcoholic system; finally, after the total flavone is turned into camellin B from camellin A by potassium carbonate, camellin B is obtained through ion exchange chromatography or recrystallization directly by the hydroalcoholic system. The invention has reasonable design, simple manufacturing process, low production cost and high yield and purity, and can obtain high-purity camellin A and camellin B through adopting recrystallization method after liquid-liquid extraction; therefore, the invention, omitting the commonly used column chromatography method and reducing the consumption of organic solvent and energy consumption to reduce environmental pollution, is suitable for industrial production. Pharmacological study shows that the method has outstanding protective action on H9C2 cardiac muscle cell line anoxic hypoxia reoxygenation model damage and can be used in curing cardiovascular system disease.

The invention discloses a pharmaceutical composition which is specially the pharmaceutical composition for treating ischemic cerebral stroke. The pharmaceutical composition is based on total weight ofthe composition and comprises 18.1%-50.9% of lactone constituents, 48.8%-81.8% of flavonoid constituents and 0.07%-6.83% of organic acid constituents. The pharmaceutical composition including the lactone constituents, the flavonoid constituents and the organic acid constituents and application thereof in the treatment of the ischemic cerebral stroke are not reported in the prior art. The pharmaceutical composition of the invention can effectively reduce cerebral infarction area of a mouse of a cerebral ischemia reperfusion model and reduce a neurological function score of the mouse, can significantly improve the activity of neuron cells of an oxygen-glucose deprivation/hypoxia-reoxygenation neuron cell damage model, has a substantial protection effect on an inflammation of LPS induction microglia, is safe and effective, and can be prepared as a drug for preventing or treating the ischemic cerebral stroke.

The invention discloses application of a whole hemp extract in preparation of drugs for preventing and treating cardiovascular and cerebrovascular diseases. The whole hemp extract is prepared by evenly mixing 0.3-99.7 parts of an industrial hemp and fructus cannabis extract and 0.3-99.7 parts of an industrial hemp and cannabis sativa L extract. Experiments prove that the whole hemp extract has the effects of improving the activity of SOD, GSH-PX and other anti-free-radical enzymes, scavenging free radicals and protecting cardio and cerebral blood vessels and tissues and preventing and controlling occurrence and development of the cardiovascular and cerebrovascular diseases. The whole hemp extract can be used for preparing the drugs for preventing and treating the cardiovascular and cerebrovascular diseases, such as cerebral ischemia, myocardial ischemia, neuronal damage caused by hypoxia-reoxygenation, cerebral infarction (stroke), cerebral thrombosis, cerebral hemorrhage, a coronary heart disease and myocardial infarction and has the good application prospect in treatment or prevention of the cardiovascular and cerebrovascular diseases.

The invention discloses a screening method of tsRNA related to myocardial ischemia reperfusion. The method is characterized by comprising the following steps of building a rat myocardial ischemia reperfusion model, and screening out differentially expressed tsRNA in a myocardial ischemia reperfusion process by adopting a sequencing method; and building an in-vivo rat myocardial ischemia reperfusion model and an in-vitro myocardial cell hypoxia reoxygenation model, and adopting real-time quantitative PCR for sequencing verification. According to the scheme, the tsRNA participates in the myocardial ischemia reperfusion injury process, and an application of the tsRNA in the aspect of myocardial ischemia reperfusion injury treatment is provided, so that a new idea is provided for people to research a pathophysiology process of myocardial ischemia reperfusion injury, and a new molecular basis or a treatment target is provided for prevention and treatment of myocardial ischemia reperfusion injury.

The invention relates to the technical field of medicines, in particular to application of an alpha-carboline derivative in preparation of an anoxia-reoxygenation injury drug against a myocardial ischemia-reperfusion injury. The compound is stable in solution, has an obvious protective activity against a myocardial anoxia-reoxygenation injury, especially an anoxia-reoxygenation injury of a myocardial ischemia-reperfusion injury, and can protect myocardium from an anoxia-reoxygenation injury at 100 mu mol/L, and thus a new option is provided for protection of the anoxia-reoxygenation injury against a myocardial ischemia-reperfusion injury and the myocardial anoxia-reoxygenation injury.

The invention relates to application of salidroside in preparation of a medicine for preventing and treating cardiovascular diseases caused by coronary artery endothelial cell injury, and belongs to the field of biological medicines. The invention provides the application of the salidroside in preparation of a medical product for preventing and treating cardiovascular diseases caused by coronary artery endothelial cell injury. The salidroside can significantly remove oxygen free radicals of coronary endothelial cells, up-regulate the activity of an antioxidant system, promote autophagy and inhibit cell apoptosis to improve coronary endothelial dysfunction caused by anoxia/reoxygenation, which indicates that the salidroside can protect coronary artery endothelial cells and relieve cardiovascular disease symptoms related to coronary artery endothelial injury.

The invention discloses a triterpenoid saponin compound. The triterpenoid saponin compound is extracted from clematis tangutica and then is subjected to separation and purification. The triterpenoid saponin compound is shown in the formula (I) and comprises an aglycone of 3 beta, 23-dihydroxyolean-18-olefine acid. The triterpenoid saponin compound has obvious effects of protecting anoxic/oxygen-rich model-induced myocardial cell injuries, can be used for preparation of a drug for treating ischemic heart diseases, is a lead compound for researching and preparing a novel drug for treating ischemic heart diseases, and can provide a clinical drug which is used for treating myocardial ischemia/reperfusion injuries and has strong activity and small toxic and side effects.

The invention belongs to the field of traditional Chinese medicines, and in particular relates to a novel application of genipin-1-[beta]-D-gentiobioside and a composition thereof. The genipin-1-[beta]-D-gentiobioside and the composition thereof can take a significant effect on treating a model rat with cerebral ischemia-reperfusion injury, obviously reduce behavioral scores of the model rat, significantly diminish the area of a brain slice infarction area of the model rat and reduce TNF-[alpha] and 1L-6 contents in serum of the model rat; an obvious therapeutic effect can be taken on a Bend.3 cell ischemic injury model which is cultured in vitro, the survival rate of injured cells can be significantly improved and a cell death-protection rate is positively related to a drug concentration; and the contents of tumor necrosis factors (TNF-[alpha]) and interleukin 6 (1L-6) in supernatant liquid of a Bend.3 cell hypoxia/reoxygenation model which is cultured in vitro can be obviously reduced. Moreover, based upon an acute toxicity test in mice and a long-term toxicity in rats, it indicates that the genipin-1-[beta]-D-gentiobioside and the composition thereof are free from toxic and side reactions.

The invention belongs to the field of natural pharmaceutical chemistry, specifically relates to a chemical activity of a natural drug, and a use of the natural drug. The structural formula of the natural compound is represented by the formula (1), and Lob is the abbreviation for the natural compound in the instruction. The present invention provides an application of the natural compound (Lob) infields of myocardial ischemia reperfusion injury protection and anoxic and re-oxygenation injury protection. In addition, the present invention further provides an application of the natural compound(Lob) in preparation of drugs for treatment of myocardial infarction.

The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In some embodiments, overexpression of the GPCR promotes survival of cardiomyocytes. In some embodiments, overexpression of the GPCR rescues cardiomyoctes from hypoxia/reoxygenation induced apoptosis. In some embodiments, the GPCR is down-regulated in individuals with congestive heart failure. Agonists of the invention are envisioned to be useful as therapeutic agents for the treatment of ischemic heart disease, including myocardial infarction, post-myocardial infarction remodeling, and congestive heart failure.

The invention relates to the technical field of medicines, in particular to application of a hederagenin derivative in preparation of a hypoxia-reoxygenation injury medicine for myocardial ischemia and reperfusion injury prevention. The compound is stable in a solution; the compound has obvious protective activity against myocardial hypoxia-reoxygenation injury, especially the hypoxia-reoxygenation injury of myocardial ischemia and reperfusion injuries; the myocardium can be well protected from hypoxia-reoxygenation injury when the concentration is 80 micromole/L, and the derivative has stronger pharmacological activity than the parent nucleus hederagenin under the same dosage, so that a new choice is provided for protection against myocardial hypoxia-reoxygenation injury and myocardial ischemia-reperfusion injury.

The invention relates to a traditional Chinese medicine extract. After traditional Chinese medicine cortex dictamni is subjected to water extraction, impurities are removed through ethanol precipitation, spray drying is carried out, and the traditional Chinese medicine extract is obtained. The traditional Chinese medicine extract has an obvious protection on hypoxia reoxygenation of myocardial cells, and can reduce the myocardial infarction area, obviously reduce the rise of the S-T section of a rat myocardial ischemia reperfusion injury electrocardiography, improve the activity of superoxide dismutase (SOD), reduce the content of malondialdehyde (MDA), reduce the activity of creatine kinase (CK), relieve the pathological lesion of myocardial ischemia reperfusion, and thus relieve the rat myocardial ischemia symptom.

The invention provides application of halofuginone in preparing drugs for treating and preventing myocardial ischemia heart diseases. It is proved that the halofuginone has the good activity of preventing and treating the myocardial ischemia heart diseases. Particularly, the invention relates to application of the halofuginone in protecting cardiomyocyte injuries induced by hypoxia reoxygenation and protecting myocardial tissue injuries induced by ischemia reperfusion.

The invention provides an in vitro method for inducing macrophage polarization to an M2 phenotype useful for tissue repair. The method described in the present invention comprises the in vitro exposure of macrophages to repeated series of hypoxia-reoxygenation. Activated M2 macrophages obtained by this method overexpress molecules important for tissue remodeling and amelioration of inflammation, such as NGAL and anti-inflammatory cytokines (IL-10). Thus, M2 macrophages obtained by this method are useful as cell therapy for tissue regeneration. The invention also provides pharmaceutical compositions and kits comprising the M2 macrophages obtained by the described method. The invention further refers to a device for inducing hypoxia and re-oxygenation conditions on isolated macrophages according to the described method.

The invention discloses a triterpenoid saponin class anti-myocardial ischemia chemical compound extracted from clematis tangutica. A molecular formula of the triterpenoid saponin class anti-myocardial ischemia chemical compound is C58H94O26. By adopting spectrum technologies such as high resolution mass spectrum and two-dimensional nuclear magnetic resonance spectrum, and chemical method, a chemical structure of the compound is confirmed as 3-0-beta-D- xylopyranose-(1->2)-alpha-L-pyran arabinose hederagenin 28-O-alpha-L-pyran rhamnose-(1->4)-beta-D- pyran glucose-(1->6)-beta-D- pyran glucose (3-O-beta-D-xylopyranosy l-(1->2)-alpha-L-arabin opyranosyl hederagenin 28-O-alpha-L-rhamnopyranosy l-(1->4)-beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranoside). Results of an in vitro anti-myocardial ischemia test shows that the chemical compound has therapeutical effects towards myocardial cell damage induced by hypoxia / re-oxygenation model. The triterpenoid saponin class anti-myocardial ischemia chemical compound extracted from the clematis tangutica can provide a lead compound for preparing a novel cardiovascular drug, thereby becoming the drug for treating cardiovascular disease.

The invention discloses application of a potent part of agilawood leaf water extract in preparation of a medicine for improving myocardial ischemia reperfusion injury, and the potent part of agilawood leaf water extract is prepared by the following steps: soaking agilawood leaves in 10-50 times by mass of water for 20-40 minutes, carrying out reflux extraction for 30-120 minutes, filtering, repeatedly carrying out reflux extraction for 2-5 times, merging filtrates, and concentrating to obtain the potent part of agilawood leaf water extract. And performing column chromatography on macroporous adsorption resin with the model of HPD-100, eluting with water, concentrating under reduced pressure, and freeze-drying to obtain the potent part of the agilawood leaf water extract. Experiments prove that the potent part of the agilawood leaf water extract can remarkably relieve myocardial cell hypoxia/reoxygenation injury of rats, and is higher in activity and wider in safety range.

The invention relates to the technical field of medicine preparation, in particular to a panax notoginseng saponins myocardial targeting liposome and a preparation method thereof. According to the present invention, the panax notoginseng total saponin myocardial targeting liposome is provided, the panax notoginseng total saponin myocardial targeting liposome comprises panax notoginseng total saponin, phospholipid, cholesterol and an esmolol analogue, a film dispersion ultrasonic method is adopted to prepare the panax notoginseng total saponin myocardial targeting liposome, the mass ratio of the phospholipid to the cholesterol is 9: 1, the ultrasonic power is 63 W, and the hydration time is 15 min; the targeting liposome has strong targeting in vivo and in vitro, has an obvious protection effect on myocardial cell inflammatory injury caused by hypoxia/reoxygenation, and has a protection effect on mice with myocardial injury caused by endotoxin in vivo.

The invention provides a medicine for resisting myocardial ischemia reperfusion injury. The medicine comprises Xinbao pills. The invention creatively discovers that the Xinbao pill can be used as a medicine for resisting myocardial ischemia-reperfusion injury; the Xinbao pill can also be used for preparing a medicine for resisting myocardial ischemia reperfusion injury, has a very strong protection effect on hypoxic reoxygenation h9c2 myocardial cells in vitro, and can inhibit h9c2 cell injury caused by hypoxic reoxygenation; the area of myocardial ischemia-reperfusion injury rat heart infarction induced by coronary artery anterior left descending branch ligation and the content of CK-MB can be remarkably reduced in vivo, and myocardial cell apoptosis is inhibited; meanwhile, expression ofheart tissue apoptosis related protein can be inhibited, the proportion of anti-apoptosis protein is increased, and expression of cell autophagy related protein Beclin-1 and LC3II is inhibited. The invention provides a theoretical basis for researching a treatment strategy of myocardial ischemia-reperfusion injury, and provides an embedding point for preparing a new medicine for resisting myocardial ischemia-reperfusion injury.

The invention discloses a salidroside-biotin small molecular probe as well as a preparation method and application thereof, and belongs to the field of medicinal chemistry. The structural formula of the small molecular probe comprises three parts, namely salidroside, biotin and a connecting chain. In-vitro activity tests show that the designed salidroside small molecular probe has good activity inprotection of hypoxia/reoxygenation-induced primary myocardial cell damage, can be used as the small molecular probe for action mechanism research of salidroside, and has a good application prospectin the medical field.

The invention provides an application of a bone marrow mesenchymal stem cell exosome. After the BMSCs-Exo is injected into the HIRI Kunming mouse, the liver function impairment can be relieved. Wherein the miR-25-3p is obviously reduced in an HIRI liver, the BMSCs and the BMSCs-Exo both contain the miR-25-3p, after the miR-25-3p mimics and the miR-25-3p mimic are respectively transferred into an HIRI mouse and an anoxic/reoxygenation AML12 hepatocyte, the expression quantity of the miR-25-3p is increased, the expression of apoptosis and inflammation related factors is reduced through qRT-PCR (quantitative reverse transcription-polymerase chain reaction) and Western blotting detection, and the apoptosis and inflammation related factors are inhibited. Moreover, by measuring the contents of aspartate transaminase (AST) and alanine transaminase (ALT) in serum and hematoxylin-eosin (HE) staining, the liver injury is reduced. In addition, the expression of genes and related proteins of the MAPK/ERK signal channel and the PI3K/AKT signal channel detected by qRT-PCR (quantitative real-time polymerase chain reaction) and Western blotting is reduced. Therefore, the miR-25-3p inhibits hepatocyte apoptosis induced by HIRI injury by inhibiting MAPK/ERK and PI3K/AKT signal channels, so that the HIRI is improved, and a new thought is provided for treatment of the HIRI.

The invention discloses a medical composition for treating myocardial hypoxia reoxygenation injury and a preparation method and application of the medical composition. The medical composition is prepared from the following raw material components in parts by weight of 8-17 parts of orientoside, 25-53 parts of quercitrin and 13-25 parts of vitexin. The medical composition can be used for treating the myocardial hypoxia reoxygenation injury, and is notable in effects.